Autopsy report · NCT05357027

HPV16 E6 TCR T Cells for Cervical Carcinoma

“Study terminated due to strategic portfolio decision to reallocate resources to higher-priority programs”

The sponsor’s own words in the registry.

Life of this trial

• Registered 7 months before it started.
• Ran for about 3 years 5 months before it stopped.
• 5 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

TCRCure Biopharma Ltd.

Sponsor type

Industry

Conditions

Cervical Carcinoma

Interventions

TC-E202 cells; IL-2; Fludarabine; Cyclophosphamide Capsules

Participants

5

Sites

1

Countries

China

Trials that died the same way

• Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy
  “Project discontinued to prioritize other key programs in portfolio” (66% match in meaning)
• Safety Study of SEA-CD40 in Cancer Patients
  “Study closed due to portfolio prioritization” (62% match in meaning)
• A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms
  “termination due to portfolio prioritization” (61% match in meaning)
• Phase 2a Study Examining the Safety and Efficacy of BOL-DP-o-04 for Treating Diabetic Neuropathy
  “study stopped due to company strategic prioritization” (58% match in meaning)
• Trastuzumab-deruxtecan in Patients With Triple-negative Metastatic HER2-Low Breast Cancer: Real-world Experience in Brazil
  “The study was stopped due to a realignment of strategic priorities” (58% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.